Ono Pharmaceutical

A Japan-headquartered global pharmaceutical company with a specialty-care profile anchored by immuno-oncology and other high-value therapeutic areas. Ono Pharmaceutical combines internal drug discovery with global partnerships and a pipeline spanning oncology, immunology and neurology.

Company Overview

Ono Pharmaceutical researches, develops, manufactures and markets prescription medicines globally. The company focuses on therapies for serious diseases with high unmet medical need, particularly cancer and immune-mediated conditions.

Its international profile has been shaped by nivolumab (Opdivo), a PD-1 checkpoint inhibitor developed with Bristol Myers Squibb that became one of the first widely used cancer immunotherapies.

Headquarters and Global Presence

Ono Pharmaceutical is headquartered in Osaka, Japan.

The company operates research, manufacturing and commercial activities across Japan, North America, Europe and Asia through subsidiaries and partnerships supporting global drug development.

Founding and History

Ono Pharmaceutical traces its corporate origins to a pharmaceutical business established in Osaka in the early 18th century.

The modern company developed through the expansion of prescription drug research and manufacturing in Japan and became publicly listed on the Tokyo Stock Exchange in 1963.

Over the past two decades, Ono has expanded its international presence through global development partnerships and oncology drug launches.

Therapy Areas and Focus

Ono Pharmaceutical concentrates its research on several core disease areas:

Oncology and cancer immunotherapy
Immunology and inflammatory diseases
Neurology and pain disorders
Specialty and rare diseases

Technology Platforms and Modalities

The company develops medicines across several modalities:

Immune checkpoint inhibitors and antibody therapeutics
Small-molecule targeted therapies
Antibody-based biologics
Discovery programs sourced through academic and biotechnology collaborations

Ono combines internal research with licensing and partnerships to expand its development pipeline.

Key Personnel

Gyo Sagara, President and Chief Executive Officer

Strategic Partnerships

Partnerships play a central role in Ono’s development strategy.

Key collaborations include:

Bristol Myers Squibb, for global development and commercialization of nivolumab (Opdivo)
Adimab, for antibody discovery programs
Academic and biotechnology collaborations supporting early drug discovery and target identification

FAQ Section

Ono focuses on specialty medicines for diseases with significant unmet medical need. Its strategy combines internal discovery with external partnerships to identify new therapeutic targets and advance drug candidates globally.

Opdivo has been a major revenue driver and a defining product for the company. The PD-1 inhibitor, developed with Bristol Myers Squibb, established Ono as an important participant in the immuno-oncology market.

Revenue from Opdivo has supported increased research investment and expansion of the company’s oncology pipeline.

The company prioritizes oncology, immunology and neurology. Oncology remains the largest focus, particularly immune-based therapies and targeted cancer drugs.

Ono combines internal discovery with external collaborations. The company works with academic institutions and biotechnology firms to identify new drug targets and technologies, which are then advanced through internal research and clinical development programs.

The pipeline includes antibody therapeutics, immune checkpoint modulators, targeted small-molecule inhibitors and experimental therapies for neurological and inflammatory diseases.

Although Japan remains its largest market, the company operates globally through subsidiaries and commercial partnerships, particularly in oncology.

Key milestones include: